Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Nordisk ASMEX:NOVOBN 79 EV-to-FCF is 29.32 as of Aug. 08, 2026, which is 2% above its 10-year median of 28.77. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN1,875.64 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 569 Drug Manufacturers companies, Novo Nordisk AS ranks worse than 58.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novo Nordisk AS's Enterprise Value is MXN3,830,123 Mil.
Novo Nordisk AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was MXN130,626 Mil. Therefore, Novo Nordisk AS's EV-to-FCF for today is 29.32.
The historical rank and industry rank for Novo Nordisk AS's EV-to-FCF or its related term are showing as below:
MEX:NOVOBN'
s EV-to-FCF Range Over the Past 10 Years
Min: 13.19 Med: 28.77 Max: 89.72
Current: 30.21
During the past 13 years, the highest EV-to-FCF of Novo Nordisk AS was 89.72. The lowest was 13.19. And the median was 28.77.
MEX:NOVOBN's EV-to-FCF is ranked worse than 58.52% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs MEX:NOVOBN: 30.21
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novo Nordisk AS (MEX:NOVOBN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novo Nordisk AS's PE Ratio (TTM) for today is calculated as:
Novo Nordisk AS's share price for today is MXN810.00.
Novo Nordisk AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN72.867.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Novo Nordisk AS EV-to-FCF Related Terms
Novo Nordisk AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NOVOBN vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's EV-to-FCF falls into.
Novo Nordisk AS's current Enterprise Value is MXN3,830,123 Mil.
Novo Nordisk AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN130,626 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NOVOBN) has a EV-to-FCF of 29.32 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Novo Nordisk AS and its competitors. This is near median its historical median of 28.77. Over the past decade, Novo Nordisk AS's EV-to-FCF has ranged from 13.19 to 89.72. According to the industry distribution chart, Novo Nordisk AS ranks #333 out of 569 companies in the Drug Manufacturers industry, placing it in the top 58.5%.
Is Novo Nordisk AS's EV-to-FCF too high?
Novo Nordisk AS's current EV-to-FCF of 29.32 is near median its 10-year median of 28.77. Over the past 10 years, this metric has ranged from a low of 13.19 to a high of 89.72. The Drug Manufacturers industry median EV-to-FCF is 21.60. Novo Nordisk AS's value of 29.32 is 35.7% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #333 out of 569 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #333 out of 569 companies for EV-to-FCF. This places Novo Nordisk AS in the lower half of its industry. The industry median EV-to-FCF is 21.60. Novo Nordisk AS's value of 29.32 is 35.7% above this benchmark. Historically, Novo Nordisk AS's own EV-to-FCF has ranged from 13.19 to 89.72 over the past decade. While the company's 10-year median is 28.77 vs. the industry median of 21.60, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.60, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current EV-to-FCF of 29.32 is 35.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current EV-to-FCF is 29.32, which is near median its own 10-year median of 28.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,875.64, compared to a current price of MXN810.00 — trading 56.8% below its estimated fair value. The current EV-to-FCF is 29.32, which is near median its 10-year median of 28.77 and 35.7% above the Drug Manufacturers industry median of 21.60. Novo Nordisk AS's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current EV-to-FCF is 29.32 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 56.8% below its estimated GF Value™ of MXN1,875.64.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
EV-to-FCF: 29.32 (near median its 10-year median of 28.77)
GF Value™: MXN1,875.64 vs. price of MXN810.00 (56.8% below fair value)
Industry Position: 35.7% above the Drug Manufacturers median (#333 of 569)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
